

REMARKS

Applicants wish to thank the Examiner for the kind telephone interview initiated by the Examiner on May 4, 2004, and the further telephonic discussions held on May 5, 2004, May 10, 2004, and May 11, 2004.

The Examiner indicated some confusion whether claims were drawn to compounds or compositions considering the terminology used, i.e., "activator", "therapeutic agent", etc. The claims have been amended to clarify that Claims 1 and 18 are drawn to compounds, Claims 4, 10, and 13 are drawn to compositions, and Claims 8, 17, and new Claims 19-29 are drawn to methods of use. Claims 2, 3, 5-7, 9, 11, 12, and 14-16 have been cancelled without prejudice or disclaimer.

The rejection of claim 18 under 35 USC 132 is respectfully traversed. The subject matter of claim 18 is fully supported in the specification as filed. For example, original claim 9 discloses all of the compounds claimed in claim 18. Reconsideration and withdrawal of the rejection are requested.

The Examiner said that he considers all the previously presented composition claims to be the same, regardless of the use recited in the preambles. While applicants do not necessarily agree, in a sincere effort to expedite prosecution of this application to an early and favorable conclusion, the composition claims reciting particular disorders have been either cancelled or amended to clarify that they are pharmaceutical compositions and contain pharmaceutically acceptable carriers or excipients as described at pages 18-19 of the specification. New Claims 19-29 round out the coverage to which applicants are entitled. Claims 19-24 merely specify the route of administration and the

dosage. Support for these claims will be found at page 19, lines 9-19, of the specification. Claims 25-29 correspond to original Claims 3-7 and 12-16. No new matter has been added.


Since all the claims are clearly in condition for allowance and are free of the prior art, whether taken singly or in combination, an early Notice of Allowance is in order and the same is most earnestly solicited.

If there are any questions regarding this amendment or the application in general, a telephone call to the undersigned would be appreciated since this should expedite the prosecution of the application for all concerned.

If necessary to effect a timely response, this paper should be considered as a petition for an Extension of Time sufficient to effect a timely response, and please charge any deficiency in fees or credit any overpayments to Deposit Account No. 05-1323 (Docket #100598.50325US).

Respectfully submitted,

September 14, 2004



Herbert I. Cantor
Registration No. 24,392
Lawrence E. Carter
Registration No. 51,532

CROWELL & MORING LLP
Intellectual Property Group
P.O. Box 14300
Washington, DC 20044-4300
Telephone No.: (202) 624-2500
Facsimile No.: (202) 628-8844
HIC:LEC:ejb
#337201v1